Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Montpellier
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
The subject must have given his informed consent and signed the consent form (if patient is protected by the law due to the study pathology, the consent will be signed his tutor or guardian ; if patient is unable to read or sign the consent form due to the study pathology, the consent will be signed by his family/trusted person)
The subject is at least 18 years old (≥).
Affiliate or beneficiary of a social security scheme
Patients with atypical form of MS
OR patients with RRMS (Relapsing-Remitting Multiple Sclerosis)
OR patients with PPMS (Primary Progressive Multiple Sclerosis)
(Patients will be matched on EDSS score (+/-1) and age (+/-5) ; Controls will be matched with patients on age)
Subject presenting or having had a history of severe group 2 or 3 head trauma according to the Masters classification
Patient receiving high dose corticosteroid therapy in the 3 months prior to inclusion in the study
You may not be if
Pregnant or lactating women.
Vulnerable people.
Simultaneous participation in any other research protocol.
Contraindication to the realization of an MRI (ferromagnetic ocular or cerebral foreign bodies close to nerve structures, pace-maker, cochlear implants)
Claustrophobic subject
Subject presenting a neurodegenerative disease (Parkinson, Alzheimer ...)
Subject presenting psychiatric disorders like psychosis, excluding anxio-depressive episode
Subject presenting a systemic pathology with neurological manifestation
Patient who is taking, or who has taken in the last year, one of the following treatments: Fingolimod, or any Monoclonal Antibody (Natalizumab, Rituximab, Ocrelizumab, Alemtuzumab ...)
Patient having had an outbreak of the disease in the 3 months prior to inclusion in the study
Subjects who are protected or unable to give their consent
Subject with anterior or progressive neurological pathology
Patient being treated or having taken any Monoclonal Antibody
In the period of exclusion relating to another protocol or for which the annual amount of the maximum indemnities of 4500 € has been reached
